Airain ltd acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 35,852 shares of the pharmaceutical company’s stock, valued at approximately $4,620,000.

Other hedge funds have also recently modified their holdings of the company. Korea Investment CORP raised its stake in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock valued at $104,000 after buying an additional 658 shares during the last quarter. Guardian Life Insurance Co. of America raised its stake in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co raised its stake in shares of Vertex Pharmaceuticals by 7.1% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,500 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 100 shares during the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $186,000. Finally, State of Alaska Department of Revenue purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $197,000. 92.87% of the stock is owned by institutional investors.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 153.27 on Monday. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The stock has a market capitalization of $38.64 billion, a P/E ratio of 147.23 and a beta of 1.77. The company has a 50 day moving average price of $149.67 and a 200-day moving average price of $120.19.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. During the same quarter last year, the business earned $0.24 earnings per share. Vertex Pharmaceuticals’s revenue was up 26.1% compared to the same quarter last year. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/28/airain-ltd-takes-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Several brokerages recently commented on VRTX. Raymond James Financial, Inc. raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price objective for the company in a report on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. lifted their price objective on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Vetr raised Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $102.09 price objective for the company in a report on Monday, May 15th. Finally, Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a report on Tuesday, July 4th. Six research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average price target of $162.88.

In related news, CFO Ian F. Smith sold 4,250 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $155.39, for a total transaction of $660,407.50. Following the sale, the chief financial officer now owns 120,138 shares in the company, valued at $18,668,243.82. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Leiden sold 147,101 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $129.50, for a total transaction of $19,049,579.50. Following the sale, the chief executive officer now owns 312,142 shares in the company, valued at approximately $40,422,389. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 751,042 shares of company stock worth $113,078,257. 1.80% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.